How to Make Psychedelic-Assisted Therapy Safer

Area of Science:

• Neuroscience
• Psychiatry
• Clinical Psychology

Background:

• Clinical revival of classic serotonergic psychedelics necessitates ethical considerations for psychedelic-assisted therapy.
• Patient vulnerability during psychedelic states is a key ethical concern requiring robust safety protocols.

Purpose of the Study:

• To examine the nature of patient vulnerability induced by psychedelics, specifically the impairment of autonomy.
• To analyze the strengths and weaknesses of existing safety measures for psychedelic-assisted therapy.
• To propose an overlooked yet effective safety measure for psychedelic sessions.

Main Methods:

• Conceptual analysis of psychedelic-induced vulnerability, focusing on diminished decision-making, controllability, and resistance to influence.
• Systematic evaluation of five proposed safety measures in the literature.
• Identification and proposal of a novel safety intervention.

Main Results:

• Psychedelic-induced vulnerability stems from impaired autonomy, affecting decision-making, control, and external influence resistance.
• Preparatory sessions, advance directives, and training/oversight are beneficial safety measures.
• Lowering dosage and omitting therapy are less effective safety strategies.

Conclusions:

• Optimizing safety in psychedelic therapy involves understanding and mitigating autonomy impairments.
• Existing safety measures can be enhanced, and novel strategies, like including a trusted companion, should be considered.
• Integrating a close person into psychedelic sessions offers a feasible and effective safety enhancement.